FMP

FMP

Enter

MLND - Millendo Therapeutic...

photo-url-https://images.financialmodelingprep.com/symbol/MLND.png

Millendo Therapeutics, Inc.

MLND

NASDAQ

Inactive Equity

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

1.06 USD

-0.06000006 (-5.66%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Revenue %

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-1.35M

-2.8M

-1.99M

-3.7M

-4.22M

-

-

-

-

-

Operating Cash Flow %

100

100

100

100

100

100

100

100

100

Cap Ex

-

-

-1.8k

-149.78k

-

-

-

-

-

-

Cap Ex %

100

100

100

100

100

-

-

-

-

Free Cash Flow

-1.35M

-2.8M

-2M

-3.85M

-4.22M

-

-

-

-

-

Weighted Average Cost Of Capital

Price

0.3

Beta

Diluted Shares Outstanding

4.9M

Costof Debt

4.15

Tax Rate

After Tax Cost Of Debt

4.15

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

0

Total Equity

1.47M

Total Capital

1.47M

Debt Weighting

0

Equity Weighting

100

Wacc

5.8

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-1.35M

-2.8M

-1.99M

-3.7M

-4.22M

-

-

-

-

-

Cap Ex

-

-

-1.8k

-149.78k

-

-

-

-

-

-

Free Cash Flow

-1.35M

-2.8M

-2M

-3.85M

-4.22M

-

-

-

-

-

Wacc

5.8

5.8

5.8

5.8

5.8

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

5.8

Free Cash Flow T1

0

Terminal Value

0

Present Terminal Value

0

Intrinsic Value

Enterprise Value

0

Net Debt

-1.84M

Equity Value

1.84M

Diluted Shares Outstanding

4.9M

Equity Value Per Share

0.38

Projected DCF

0.3752 0.2%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep